Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510618 | 0.83 | NOS1 (0.44) | NOS1PDPK1JAK2MAP2K4MAPK10 | |
| SCHEMBL24819259 | 0.81 | PDPK1 (0.60) | PDPK1JAK2 | |
| SCHEMBL18764465 | 0.79 | PDPK1 (0.44) | NOS1PDPK1JAK2HSP90AB1FGFR1 | |
| SCHEMBL14755254 | 0.79 | AXL (0.49) | PDPK1JAK2FGFR1FGFR2MAPT | |
| SCHEMBL31735799 | 0.79 | MAP2K4 (0.47) | NOS1MAP2K4PARP1 | |
| SCHEMBL1330584 | 0.79 | PDPK1 (0.63) | NOS1PDPK1JAK2FGFR1MAPK14 | |
| SCHEMBL14737362 | 0.79 | ITK (0.50) | MAP2K4ITK | |
| SCHEMBL2595185 | 0.79 | MAP2K4 (0.56) | MAP2K4ITK | |
| SCHEMBL21937470 | 0.79 | ADORA2A (0.46) | NOS1PDPK1JAK2HSP90AB1FGFR1 | |
| SCHEMBL13184208 | 0.79 | HSP90AB1 (0.59) | PDPK1JAK2HSP90AB1FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016108106-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AXITINIB | SHILPA MEDICARE LIMITED (IN) | 2016-07-07 | — | — | WO | disclosed |
| EP-2163544-A1 | Methods of preparing indazole compounds | Pfizer, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2163544-A1 | Methods of preparing indazole compounds | Pfizer, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1614683-B1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMA (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1218348-B1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2007-10-24 | — | — | EP | disclosed |
| CN-101052633-A | Methods of preparing indazole compounds | AGOURON PHARMA (US) | 2007-10-10 | — | — | CN | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS. INC. | 2005-06-09 | — | — | US | disclosed |
| US-6891044-B2 | Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6884890-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | NOS1 275/4885PDPK1 19/4885JAK2 123/4885 |
| US-20070203196-A1 | METHODS OF PREPARING INDAZOLE COMPOUNDS | CDK1, CDK2, CCNI | NOS1 1001/4885PDPK1 64/4885JAK2 788/4885 |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | NOS1 275/4885PDPK1 19/4885JAK2 123/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | NOS1 275/4885PDPK1 19/4885JAK2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.